The U.S. Food and Drug Administration today approved the use of Vascepa (icosapent ethyl) as an adjunctive (seco

ndary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of f

at in the blood) of 150 milligrams per deciliter or higher. Vascepa is the first FDA approved drug to reduce cardiovas

cular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.